In the wake of the increase in Current Liabilities in the second quarter 2025, Quick Ratio fell to 24.04 below Tourmaline Bio Inc average.

Within Biotechnology & Pharmaceuticals industry 9 other companies have achieved higher Quick Ratio than Tourmaline Bio Inc in second quarter 2025. While Quick Ratio total ranking in the second quarter 2025 has deteriorated compared to the prior quarter from 150 to 218.

Explain Quick Ratio?
How much Cash & cash equivalents TRML�s has?
What are TRML�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

TRML Quick Ratio	(Jun 30 2025) Q2	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2
Y / Y Current Liabilities Change	56.42 %	53.84 %	78.11 %	-10.13 %	-37.23 %
Y / Y Cash & cash equivalent Change	-17.37 %	-14.93 %	27.27 %	78.45 %	31.02 %
Quick Ratio MRQ	24.04	33.57	28.99	38.7	45.52
TRML's Total Ranking	# 218	# 150	# 196	# 135	# 126
Seq. Current Liabilities Change	33.99 %	-16.65 %	22.31 %	14.51 %	31.78 %
Seq. Cash & cash equivalent Change	-4.04 %	-3.48 %	-8.38 %	-2.63 %	-1.2 %

Quick Ratio second quarter 2025 Company Ranking
Within:	No.
Biotechnology & Pharmaceuticals Industry	# 10
Healthcare Sector	# 42
Overall Market	# 212

Quick Ratio Statistics
High	Average	Low
60.71	33.2	3.91
(Mar 31 2024)		(Dec 31 2022)

Financial Statements
Tourmaline Bio Inc 's Current Liabilities	$ 10 Millions	Visit TRML's Balance sheet
Tourmaline Bio Inc 's Cash & cash equivalent	$ 239 Millions	Visit TRML's Balance sheet
Source of TRML's Sales		Visit TRML's Sales by Geography

Cumulative Tourmaline Bio Inc 's Quick Ratio

TRML's Quick Ratio for the trailling 12 Months

TRML Quick Ratio	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months
Y / Y Current Liabilities TTM Growth	38.17 %	6.81 %	-18.07 %	-23.11 %	-23.1 %
Y / Y Cash & cash equivalent TTM Growth	9.03 %	23.32 %	54.24 %	100.18 %	65.78 %
Quick Ratio TTM	30.65	35.99	41.01	45.47	38.84
Total Ranking TTM	# 2070	# 1845	# 1800	# 1774	# 1990
Seq. Current Liabilities TTM Growth	11.97 %	9.49 %	16.64 %	-3.38 %	-13.44 %
Seq. Cash & cash equivalent TTM Growth	-4.66 %	-3.9 %	5.19 %	13.14 %	7.83 %

Quick ratio ranking by company, industry and sector >> Back to TRML Financial Strength Comparisons >> Go to Compare TRML Quick Ratio to its Competitors

News about Tourmaline Bio Inc Quick Ratio

Tourmaline Bio's Ambitious Public Offering Signals Game-Changing Advances in Immune and Inflammatory Disease Treatment

Tourmaline Bio Inc., a leading clinical biotechnology company, has announced the launch of a proposed underwritten public offering of its common stock. The company aims to develop innovative medicines that can significantly enhance the lives of patients suffering from immune and inflammatory diseases. All shares of common stock to be sold in the offering will be offered by Tourmaline Bio Inc., with the underwriters potentially having the option to purchase additional shares. However, the completion and terms of the offering are subject to market conditions and other factors, and there is no guarantee of its success.
Financially, Tourmaline Bio Inc. has witnessed a positive development as its Current Liabilities decreased at a faster rate than its Cash and cash equivalents. This improvement has led to an increased Quick Ratio of 18.14 for the company. On a trailing twelve months basis, despite a decrease in Current Liabilities to $8.105 million, the cumulative Quick Ratio dropped to 16.21, which is below the average Quick Ratio for the company.
Assessment:
The proposed public offering of common stock by Tourmaline Bio Inc. showcases the company s ambition to raise capital for its transformative medicines. By utilizing the public markets, the company aims to further develop groundbreaking treatments that can positively impact patients with life-altering immune and inflammatory diseases. However, the success of the offering will depend on market conditions and other external factors, leaving some uncertainty regarding its completion and terms.

On the trailing twelve months basis Due to growth in Current Liabilities in the Q2 2025 to $9.95 millions, cumulative Quick Ratio decreased to 30.65 above the TRML average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 129 other companies have achieved higher Quick Ratio than Tourmaline Bio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2025 from 1845 to 2070.

Explain Quick Ratio?
How much Cash & cash equivalents TRML�s has?
What are TRML�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Biotechnology & Pharmaceuticals Industry	# 130
Healthcare Sector	# 727
Within the Market	# 2070

trailing twelve months Quick Ratio Statistics
High	Average	Low
45.47	30.35	16.21
(Sep 30 2024)		(Sep 30 2023)

Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry	Quick Ratio	Jun 30 2025 MRQ Cash & cash equivalent	Jun 30 2025 MRQ Current Liabilities
Viskase Holdings inc	55.16	$ 44.294 Millions	$ 0.803 Millions
Tarsus Pharmaceuticals Inc	32.82	$ 381.143 Millions	$ 11.612 Millions
Voyager Therapeutics Inc	31.36	$ 433.653 Millions	$ 13.829 Millions
Hillevax Inc	25.96	$ 159.547 Millions	$ 6.147 Millions
Tectonic Therapeutic Inc	25.30	$ 287.381 Millions	$ 11.361 Millions
Tourmaline Bio Inc	24.04	$ 239.234 Millions	$ 9.950 Millions
Cg Oncology Inc	21.76	$ 661.052 Millions	$ 30.381 Millions
Artiva Biotherapeutics Inc	20.19	$ 142.400 Millions	$ 7.053 Millions
Kymera Therapeutics Inc	19.64	$ 665.445 Millions	$ 33.874 Millions
Crispr Therapeutics Ag	16.49	$ 1,721.237 Millions	$ 104.362 Millions
Apogee Therapeutics Inc	16.02	$ 505.420 Millions	$ 31.551 Millions
Cidara Therapeutics Inc	15.80	$ 510.575 Millions	$ 32.318 Millions
Qiagen N v	15.12	$ 1,098.918 Millions	$ 72.656 Millions
Inhibikase Therapeutics Inc	14.89	$ 87.666 Millions	$ 5.887 Millions
Maze Therapeutics Inc	13.29	$ 264.541 Millions	$ 19.900 Millions
Genenta Science S p a	13.29	$ 31.527 Millions	$ 2.372 Millions
Imagenebio Inc	13.06	$ 95.642 Millions	$ 7.324 Millions
In8bio Inc	13.04	$ 13.226 Millions	$ 1.014 Millions
Pharmacyte Biotech Inc	12.67	$ 13.440 Millions	$ 1.061 Millions
Protara Therapeutics Inc	12.52	$ 122.216 Millions	$ 9.761 Millions
Taysha Gene Therapies Inc	12.34	$ 312.761 Millions	$ 25.349 Millions
Cargo Therapeutics Inc	12.08	$ 252.567 Millions	$ 20.908 Millions
Aura Biosciences Inc	11.94	$ 177.311 Millions	$ 14.852 Millions
Kalaris Therapeutics Inc	11.56	$ 88.426 Millions	$ 7.651 Millions
Entera Bio Ltd	11.28	$ 10.858 Millions	$ 0.963 Millions
Prokidney Corp	10.77	$ 294.728 Millions	$ 27.359 Millions
Engene Therapeutics Inc	10.68	$ 201.913 Millions	$ 18.913 Millions
Titan Pharmaceuticals Inc	10.66	$ 2.803 Millions	$ 0.263 Millions
Century Therapeutics inc	10.43	$ 155.843 Millions	$ 14.948 Millions
Acumen Pharmaceuticals Inc	10.42	$ 143.369 Millions	$ 13.753 Millions

Date modified: 2026-09-08T22:38:36+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.